- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05420753
Body Composition Changes After TIPS and Associated Clinical Outcomes
Single-center Randomized Controlled Trial to Evaluate Body Composition Changes and Clinical Outcomes After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation in Patients With Cirrhosis and Complications of Portal Hypertension Awaiting Liver Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sarcopenia (loss of muscle mass) and frailty (loss of muscle function) have increasingly become recognized as major prognostic factors in predicting morbidity and mortality with several disease states, including cirrhosis. Cirrhosis represents end-stage liver disease and is complicated by a multitude of clinical sequelae, such as variceal hemorrhage, ascites, renal insufficiency, hepatic encephalopathy, hepatopulmonary syndrome, cardiac dysfunction, infection and hepatocellular carcinoma. To date, liver transplantation remains the only prospect for a curative treatment. As the liver is the primary metabolic organ, sarcopenia is prevalent in cirrhosis, afflicting 30-70% of patients. Observational studies have implicated sarcopenia as an independent risk factor for morbidity and mortality in all clinical sequelae of cirrhosis. Moreover, sarcopenia and frailty have been shown to increase morbidity and mortality of transplant eligible patients on the liver transplant waitlist, as well as mortality of patients after liver transplant. Given the prevalence of sarcopenia and frailty in this patient population, and the severe clinical impacts, addressing these adverse predictors may have profound implications for the outcomes of patients with cirrhosis.
Cirrhosis often leads to portal hypertension, complications of which include lower extremity edema, ascites, hepatic hydrothorax, variceal bleeding, portal hypertensive gastropathy, portal vein thrombosis, and hepatic encephalopathy. Patients with cirrhosis and complications of portal hypertension are currently managed in several ways in clinical practice:
- medical management, including diuretics and non-selective beta blocker therapy
- endoscopic options include variceal banding or glue embolization
- invasive options include large-volume paracentesis (LVP) or transjugular intrahepatic portosystemic shunt (TIPS) creation.
Since 1988, the Liver Transplant Program at OHSU has been successfully treating waitlisted cirrhotic patients with complications of portal hypertension using a combination of these therapies. TIPS creation, particularly in the current era of stent grafts with a dedicated device for this procedure, has been a part of managing patients with cirrhosis as a bridge to transplant for two decades. Depending on the indication, patients can be treated with a combination of these therapies often with significant overlap. For example, a given patient with portal hypertension and ascites may be managed with diuretics and serial LVP vs. TIPS creation, and a given patient with variceal bleeding may be treated with beta-blockers and endoscopic banding vs. TIPS creation.
Of relevance to the proposed trial, recent observational studies have demonstrated significant reversal of sarcopenia after TIPS creation, and this reversal has been strongly correlated with improved survival and less hepatic encephalopathy. Moreover, the time course of muscle gains has been observed to occur within the first 6 months of TIPS creation, critical for patients awaiting liver transplantation, as benefits would occur during typical transplant waitlist time periods. Thus, TIPS creation may represent a major unmet need to address sarcopenia and frailty in patients with cirrhosis, and represents an intervention with potential to reverse this debilitating condition and improve clinical outcomes. Putative mechanisms for how TIPS creation may improve body composition include decreased congestive enteropathy resulting in improved gut nutrient absorption, decrease in metabolic burden from a hyperdynamic cardiopulmonary status in the setting of fluid overload, improvement in renal function, and changes in the gut microbiome resulting in conversion from a catabolic to an anabolic state. A major gap in knowledge, however, remains whether TIPS creation can directly reverse muscle loss. Furthermore, whether reversal of muscle loss results in improved measures of strength, physical performance and clinical outcomes has not been prospectively studied. In this proposal, the investigators plan to address this major knowledge gap through a pilot prospective randomized controlled trial tracking patients managed with TIPS creation compared to those managed without TIPS to determine whether these observational findings can be seen in a randomized cohort.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Khashayar Farsad, MD
- Phone Number: 503-494-7660
- Email: farsad@ohsu.edu
Study Contact Backup
- Name: Lori Russell, RN
- Phone Number: 503-494-7660
- Email: watsonlo@ohsu.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
Contact:
- Khashayar Farsad, MD
- Phone Number: 503-494-7660
- Email: farsad@ohsu.edu
-
Contact:
- Lori Russell, RN
- Phone Number: 503-494-7660
- Email: watsonlo@ohsu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients >18 <99 with cirrhosis wait listed for liver transplantation
- Evidence of complications of portal hypertension:
- Ascites or hydrothorax requiring escalation of diuretic medication
- Persistent ascites or hydrothorax despite diuretic use, or intolerance of diuretic use
- Gastrointestinal varices and blood loss anemia or history of variceal hemorrhage
- Portal hypertensive gastropathy and blood loss anemia
- Chronic portal vein thrombosis requiring recanalization and TIPS for transplant
Exclusion Criteria:
- Hepatocellular carcinoma or other active malignancy
- Recurrent overt hepatic encephalopathy
- Uncontrolled coagulopathy with maximum amplitude (MA) <30 on thromboelastography
- Bacteremia or sepsis
- MELD > 25
- Pregnant
- Decisionally impaired individuals
- Need for emergency TIPS creation
- Patients who do not have acceptable alternatives to TIPS creation to manage their disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TIPS
Patients in this arm will undergo TIPS creation in addition to their current management.
|
During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle.
The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
|
No Intervention: Standard of care
Patients in this arm will continue to be treated with their current management
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body composition changes
Time Frame: Start to 2 years after enrollment
|
Muscle and fat content as assessed by CT scan
|
Start to 2 years after enrollment
|
Short Performance Physical Battery test
Time Frame: Start to 6 months after enrollment
|
Brief physical test for balance with feet together (seconds), gait speed walking 4 meters (seconds), time to stand from a chair (seconds).
These are aggregated together to a unified score.
|
Start to 6 months after enrollment
|
Liver Frailty test
Time Frame: Start to 6 months after enrollment
|
Brief physical test for balance with feet together (seconds), time to stand from a chair (seconds), and grip strength (kilograms of force).
These are aggregated together to a unified score.
|
Start to 6 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic Liver Disease Quality of Life Questionnaire
Time Frame: Start to 6 months after enrollment
|
Quality of life assessment using 29 questions regarding experience of various symptoms graded on a scale of 1-7 each, with 1 being worse (all of the time) and 7 being the best (none of the time).
|
Start to 6 months after enrollment
|
Overall survival
Time Frame: Start to 2 years after enrollment
|
Survival time
|
Start to 2 years after enrollment
|
Transplant complications
Time Frame: Start to 30 days after transplant
|
Complications while on transplant waitlist as well as after transplant
|
Start to 30 days after transplant
|
Cardiac function
Time Frame: Start to 6 months after enrollment
|
Right and left ventricular function noted by echocardiography
|
Start to 6 months after enrollment
|
Liver function tests
Time Frame: Start to 6 months after enrollment
|
Serum tests for total bilirubin (mg/dL), albumin (g/dL), sodium (mmol/L), creatinine (mg/dL), international normalized ratio.
These values will be combined in the MELD score = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43, and MELD-Na score = MELD + 1.32 x (137 - Na) - [0.033 x MELD*(137 - Na)]
|
Start to 6 months after enrollment
|
Cardiac mass
Time Frame: start to 6 months after enrollment
|
Myocardial mass as measured by echocardiography
|
start to 6 months after enrollment
|
Serum ammonia
Time Frame: start to 6 months after enrollment
|
serum ammonia level (micromol/L)
|
start to 6 months after enrollment
|
Serum glucose
Time Frame: start to 6 months after enrollment
|
serum glucose level (mg/dL)
|
start to 6 months after enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool microbiome genomic assessment
Time Frame: Start to 6 months after enrollment
|
Stool sample using DNAGenotek Omni-gene Stool collection kit to assess for bacterial complement in stool
|
Start to 6 months after enrollment
|
Lipocalin-2 biomarker assessment
Time Frame: Start to 6 months after enrollment
|
Lipocalin-2 transcription and expression (RNA sequencing/Elisa/Western Blot) in serum samples
|
Start to 6 months after enrollment
|
IL-6 biomarker assessment
Time Frame: Start to 6 months after enrollment
|
IL-6 immunoassay assessment of serum (pg/mL)
|
Start to 6 months after enrollment
|
Salivary cortisol biomarker assessment
Time Frame: Start to 6 months after enrollment
|
salivary cortisol (mmol/L)
|
Start to 6 months after enrollment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00022853
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation
-
W.L.Gore & AssociatesRecruiting
-
Fei GaoNot yet recruiting
-
University of Kansas Medical CenterCompleted
-
National Institute of Diabetes and Digestive and...CompletedLiver Cirrhosis | Esophageal and Gastric VaricesUnited States
-
Enlight Medical Technologies (Shanghai) Co., LtdRecruiting
-
Instituto Nacional de Ciencias Medicas y Nutricion...RecruitingPortal Vein ThrombosisMexico
-
West China HospitalCompletedHepatopulmonary SyndromeChina
-
Medical College of WisconsinRadiological Society of North AmericaActive, not recruitingRefractory AscitesUnited States
-
University Hospital FreiburgRecruitingLiver Cirrhosis | Portal Hypertension | Portal Vein Thrombosis | Non-Cirrhotic Portal Hypertension | Budd Chiari Syndrome | Portal Systemic ShuntGermany
-
Argon Medical DevicesAvaniaTerminatedLiver Diseases | Vascular Diseases | Portal Hypertension | Ascites Hepatic | HydrothoraxUnited States